HIMS Rebounds 4.36% on Novo Nordisk Partnership, $700M Trading Volume Ranks 175th

Market Snapshot

On March 19, 2026, Hims & Hers Health (HIMS) closed with a 4.36% increase, marking a positive performance despite recent volatility. The stock saw a trading volume of $0.70 billion, ranking 175th in daily trading activity. This gain follows a sharp 7% decline on March 17, driven by heavy trading and insider selling, which pushed the stock near its 50-day moving average of $23.43 but well below its 200-day average of $37.08. The stock’s price of $24.16 at close reflects a partial recovery after a week of mixed sentiment.

Key Drivers Behind HIMS’s Performance

Insider Selling and Investor Sentiment

Significant insider selling on March 17 raised concerns among investors. COO Michael Chi sold 97,289 shares (~$2.4 million), while Irene Becklund and Soleil Boughton reduced their stakes by 38.72% and 1.53%, respectively. These transactions, disclosed via SEC filings, were executed under Rule 10b5-1 trading plans, but large insider sales often signal caution. Chi’s move alone represented a 19.28% reduction in his ownership, while Becklund’s sale highlighted a dramatic trimming of her position. While insiders retained substantial holdings post-sale, the timing and volume of these transactions likely contributed to the 7% drop on March 17.

Strategic Partnership with Novo Nordisk

A major positive development was HIMS’s expanded collaboration with Novo Nordisk, granting telehealth access to Ozempic and Wegovy. This partnership, which resolved prior legal disputes, enables HIMS to offer GLP-1 drugs for weight loss and diabetes management, broadening its market reach. The pre-launch waitlist for these drugs could drive patient acquisition, though analysts note pricing pressures from competitors like Eli Lilly and generic alternatives. Novo Nordisk’s endorsement also enhances HIMS’s credibility in the GLP-1 space, potentially attracting new users and improving long-term growth prospects.

Earnings Beat and Analyst Outlook

HIMS reported Q4 earnings of $0.08 per share, exceeding expectations of $0.02, with revenue rising 28.4% year-over-year to $617.8 million. Despite this, the stock remains below its 52-week high of $70.43, trading at a price-to-earnings ratio of 45.55. Analysts remain divided: 13 of 21 maintain a “Hold” rating, while three upgraded to “Buy” (e.g., Needham & Company) and one to “Sell.” The average price target of $31.29 implies ~26% upside from the March 19 close. However, mixed sentiment persists due to concerns over GLP-1 margin compression and execution risks tied to the Novo Nordisk partnership.

Institutional Ownership and Market Positioning

Institutional investors have shown increased interest, with entities like Farallon Capital and Steadview Capital boosting holdings in Q3 2025. Farallon’s stake alone is valued at $609.6 million, reflecting confidence in HIMS’s growth narrative. The company’s 63.52% institutional ownership underscores its appeal to long-term investors. However, the stock’s high beta of 2.55 and elevated debt-to-equity ratio (1.80) highlight financial risks, particularly in a rising interest rate environment.

Balancing Growth and Challenges

While the Novo Nordisk deal and strong Q4 results provide a bullish foundation, near-term headwinds include competitive pricing pressures and insider selling. Analysts like Needham & Company see long-term potential in GLP-1 demand, but execution risks—such as conversion rates from the pre-launch waitlist—remain critical. The stock’s 4.36% rebound on March 19 suggests investor optimism about these strategic moves, though the path to $31.29 will require sustained earnings growth and favorable market conditions.